Independence Day Special: 50% Off Premium Subscription 🕑 ... >> Independence Day Special: 50% Off >>
$1.81
-0.120 (-6.22%)
At Close: Jul 03, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Processa Pharmaceuticals Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 64.91. In total, the insiders bought 3 005 145 and sold 402 801 PCSA shares in the last 100 trades.

Insider Power

(Last 100 transactions) 		64.91
Buy 3 005 145 Shares
Sell 402 801 Shares

Historical Insider Trades

Date Type Action Person Amount
Feb 07, 2024 Common Stock Buy Young David 21 000
Feb 06, 2024 Common Stock Buy Young David 20 000
Feb 01, 2024 Common Stock Buy Lin Patrick 1 500
Jan 31, 2024 Common Stock Buy Lin Patrick 2 500
Jan 30, 2024 Common Stock Buy Ng George K 10 000
Jan 30, 2024 Common Stock Buy Yorke Justin W 8 000
Jan 01, 2024 Common Stock Buy Young David 1 675
Jan 01, 2024 Common Stock Sell Young David 518
Jan 01, 2024 Restricted Stock Units Sell Young David 1 675
Jan 01, 2024 Restricted Stock Units Sell Stanker James H 1 675
Jan 01, 2024 Common Stock Buy Stanker James H 1 675
Jan 01, 2024 Common Stock Sell Stanker James H 518
Jan 01, 2024 Common Stock Buy Lin Patrick 1 675
Jan 01, 2024 Common Stock Sell Lin Patrick 539
Jan 01, 2024 Restricted Stock Units Sell Lin Patrick 1 675
Jan 01, 2024 Restricted Stock Units Sell Bigora Sian 1 675
Jan 01, 2024 Common Stock Buy Bigora Sian 1 675
Jan 01, 2024 Common Stock Sell Bigora Sian 368
Jan 01, 2024 Restricted Stock Units Sell Guy Wendy 1 675
Jan 01, 2024 Common Stock Buy Guy Wendy 1 675
Jan 01, 2024 Common Stock Sell Guy Wendy 368
Nov 21, 2023 Common Stock Sell Yorke Justin W 55 267
Oct 12, 2023 Common Stock Buy Yorke Justin W 6 000
Oct 12, 2023 Common Stock Buy Guy Wendy 14 771
Oct 12, 2023 Common Stock Buy Ng George K 100 000
Click to get the best stock tips daily for free!

About Processa Pharmaceuticals Inc.

Processa Pharmaceuticals. Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selectiv... PCSA Profile

Golden Star

Ticker Date Change Price
PRU Jul 01 0.96% $117.53
PEG Jul 01 0.421% $73.63
ALSN Jul 01 1.21% $74.96
INTC Jul 01 1.26% $30.84
TXN Jul 01 2.23% $194.60
ODD Jul 01 3.98% $39.17
RDN Jun 28 0.257% $31.10
PDBC Jun 28 1.78% $14.05
SLM Jun 28 0.433% $20.79
VIGI Jun 28 1.00% $81.28
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT